• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬肺动脉高压的治疗:他达拉非是西地那非的合适替代药物吗?

Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?

作者信息

Wung Deanna

机构信息

University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.

出版信息

Int J Pharm Compd. 2013 Jan-Feb;17(1):24-7.

PMID:23627243
Abstract

The drugs tadalafil and sildenafil share the same mechanism. Although more research is necessary to solidify the recommendation of the routine use of tadalafil, human and dog data combined with pharmacokinetic data suggest that dogs may be safely treated for canine pulmonary arterial hypertension with tadalafil for the convenience of less frequent dosing, with effects similar to sildenafil. While more costly, the use of tadalafil has positive implications in improving compliance and, therefore, therapeutic outcomes in canine pulmonary arterial hypertension. This article explores the data for the use of tadalafil in canine pulmonary arterial hypertension and provides example compounded preparations.

摘要

他达拉非和西地那非具有相同的作用机制。虽然需要更多研究来确定常规使用他达拉非的建议,但结合人体和犬类数据以及药代动力学数据表明,他达拉非可安全用于治疗犬类肺动脉高压,因其给药频率较低,且效果与西地那非相似。虽然他达拉非成本更高,但在改善犬类肺动脉高压的依从性以及治疗效果方面具有积极意义。本文探讨了他达拉非用于犬类肺动脉高压的数据,并提供了复方制剂示例。

相似文献

1
Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?犬肺动脉高压的治疗:他达拉非是西地那非的合适替代药物吗?
Int J Pharm Compd. 2013 Jan-Feb;17(1):24-7.
2
Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
Int J Cardiol. 2008 Apr 25;125(3):416-7. doi: 10.1016/j.ijcard.2007.01.046. Epub 2007 Apr 3.
3
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.西地那非作为肺动脉高压治疗的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1193-205. doi: 10.1517/17425255.2013.804063. Epub 2013 Jun 12.
4
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.肺动脉高压患者从西地那非转为他达拉非的安全性、耐受性和疗效。
Cardiovasc Ther. 2013 Oct;31(5):274-9. doi: 10.1111/1755-5922.12038.
5
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.磷酸二酯酶 5 抑制剂在肺动脉高压中的应用。
Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19.
6
Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.采用 LC-MS/MS 法检测和验证定量人血浆中的磷酸二酯酶 5 抑制剂西地那非、伐地那非、他达拉非及其 2 种代谢物——在法医和治疗药物监测案例中的应用。
Ther Drug Monit. 2012 Dec;34(6):729-35. doi: 10.1097/FTD.0b013e31827318b8.
7
Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.从西地那非转换为他达拉非:肺动脉高压(SITAR)研究中的结果。
J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):550-7. doi: 10.1177/1074248414528066. Epub 2014 Apr 17.
8
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].[用于肺动脉高压的5型磷酸二酯酶抑制剂]
Nihon Rinsho. 2008 Nov;66(11):2157-61.
9
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].[5型磷酸二酯酶抑制剂治疗肺动脉高压]
Anadolu Kardiyol Derg. 2010 Sep;10 Suppl 2:16-8. doi: 10.5152/akd.2010.125.
10
Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.他达拉非与西地那非对儿童和青少年肺动脉高压的治疗效果及副作用比较。
Pediatr Cardiol. 2014 Apr;35(4):699-704. doi: 10.1007/s00246-013-0840-z. Epub 2013 Nov 20.